Ariad Pharmaceuticals (ARIA) Given Coverage Optimism Score of -0.06

News coverage about Ariad Pharmaceuticals (NASDAQ:ARIA) has been trending somewhat negative this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a media sentiment score of -0.06 on Accern’s scale. Accern also assigned news articles about the pharmaceutical company an impact score of 45.6013676935627 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Ariad Pharmaceuticals (NASDAQ ARIA) traded up $0.04 during trading on Wednesday, hitting $23.99. 7,220,900 shares of the stock traded hands, compared to its average volume of 15,701,480. Ariad Pharmaceuticals has a 52 week low of $4.67 and a 52 week high of $23.99. The company has a quick ratio of 3.15, a current ratio of 3.17 and a debt-to-equity ratio of -11.28.

ILLEGAL ACTIVITY WARNING: “Ariad Pharmaceuticals (ARIA) Given Coverage Optimism Score of -0.06” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/27/ariad-pharmaceuticals-aria-given-coverage-optimism-score-of-0-06.html.

About Ariad Pharmaceuticals

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Insider Buying and Selling by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

What are top analysts saying about Ariad Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ariad Pharmaceuticals and related companies.

Ariad Pharmaceuticals (ARIA) Given Coverage Optimism Score of -0.06

News coverage about Ariad Pharmaceuticals (NASDAQ:ARIA) has been trending somewhat negative this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a media sentiment score of -0.06 on Accern’s scale. Accern also assigned news articles about the pharmaceutical company an impact score of 45.6013676935627 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Ariad Pharmaceuticals (NASDAQ ARIA) traded up $0.04 during trading on Wednesday, hitting $23.99. 7,220,900 shares of the stock traded hands, compared to its average volume of 15,701,480. Ariad Pharmaceuticals has a 52 week low of $4.67 and a 52 week high of $23.99. The company has a quick ratio of 3.15, a current ratio of 3.17 and a debt-to-equity ratio of -11.28.

ILLEGAL ACTIVITY WARNING: “Ariad Pharmaceuticals (ARIA) Given Coverage Optimism Score of -0.06” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/27/ariad-pharmaceuticals-aria-given-coverage-optimism-score-of-0-06.html.

About Ariad Pharmaceuticals

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Insider Buying and Selling by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

What are top analysts saying about Ariad Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ariad Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit